Status:
ACTIVE_NOT_RECRUITING
Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Ovarian Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This trial studies how well a diet high in magnesium works in preventing low blood magnesium levels (hypomagnesemia) in patients with ovarian cancer receiving carboplatin chemotherapy. Hypomagnesemia ...
Detailed Description
PRIMARY OBJECTIVE: I. Evaluate intervention feasibility. SECONDARY OBJECTIVE: I. Evaluate occurrence of hypomagnesemia and the need for a pharmacy regimen including oral and intravenous magnesium d...
Eligibility Criteria
Inclusion
- Patients with previously untreated ovarian cancer.
- Receiving carboplatin-containing chemotherapy of at least 6 consecutive cycles.
- Able to tolerate an oral diet.
Exclusion
- Prior platinum-based chemotherapy.
- Serum creatinine level \> 1.4 mg/dL prior to treatment.
- Artificial nutrition (e.g. Ensure or Boost) accounts for \> 50% of total calorie intake.
Key Trial Info
Start Date :
April 23 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2026
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04310826
Start Date
April 23 2019
End Date
April 1 2026
Last Update
August 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030